| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/03/2005 | WO2005009992A1 Cyclohexanecarboxylic acid compound |
| 02/03/2005 | WO2005009976A1 Pyridazinyl- piperazines and their use as histamine h3 receptor ligands |
| 02/03/2005 | WO2005009974A1 Imidazole compounds and uses thereof |
| 02/03/2005 | WO2005009942A1 Optically active substituted phenylpropionic acid derivative |
| 02/03/2005 | WO2005009471A1 Composition for lowering blood-sugar level |
| 02/03/2005 | WO2005009469A1 Novel drug for regulating blood sugar and method of screening the same |
| 02/03/2005 | WO2005009445A1 A1 adenosine receptor antagonists |
| 02/03/2005 | WO2005009276A2 Microbial cellulose wound dressing |
| 02/03/2005 | WO2005000339A3 Melanocortin receptor 4(mc4) agonists and their uses |
| 02/03/2005 | WO2004110472A3 Fusion proteins |
| 02/03/2005 | WO2002096360A3 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 02/03/2005 | US20050027114 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 02/03/2005 | US20050027009 New derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 02/03/2005 | US20050026990 N-[(3S)-1-hydroxy-2-oxopyrrolidinyl]-N-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonamide or derivatives to treat Respiratory system disorders; arthritis, and bone disorders |
| 02/03/2005 | US20050026989 treatment or prophylaxis of cardiovascular disease, metabolic disease, cancerous disease, or fibrotic disease; arrhythmias, life-threatening cardiac ventricular fibrillation, myocardial infarction, angina pectoris; ischemic states of the heart, diabetes |
| 02/03/2005 | US20050026988 Cyclopenta'b! indole derivatives as spla inhibitors |
| 02/03/2005 | US20050026986 Use of central cannabinoid receptor antagonists for the preparation of drugs |
| 02/03/2005 | US20050026983 Imidazole compounds and uses thereof |
| 02/03/2005 | US20050026977 Controlling dosage; sustained and significant weight loss in an overweight subject |
| 02/03/2005 | US20050026973 New heterocyclic oxime compounds |
| 02/03/2005 | US20050026969 Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors |
| 02/03/2005 | US20050026967 Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases |
| 02/03/2005 | US20050026963 Pyrazole substituted directly, or by a bridge, with a heteroaryl group containing N adjacent to the point of connection of the heteroaryl useful in the treatment of psychiatric and mood disorders such as, schizophrenia, anxiety, depression, bipolar disorder, circadian rhythm and sleep disorders |
| 02/03/2005 | US20050026956 Carbinols for the treatment of neuropathic dysfunction |
| 02/03/2005 | US20050026945 Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors |
| 02/03/2005 | US20050026942 Chemokine receptor binding heterocyclic compounds |
| 02/03/2005 | US20050026931 Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluropropanamide derivatives which elevate pyruvate dehydrogenase activity |
| 02/03/2005 | US20050026915 As melanin concentrating hormone (MCH)receptor antagonists, for prevention or treatment of obesity or eating disorders; (2E)-3-(4-chlorophenyl)-N-[2-(dimethylamino)quinolin-6-yl]prop-2-enamide |
| 02/03/2005 | US20050026908 Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer |
| 02/03/2005 | US20050026905 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 02/03/2005 | US20050026904 Cathepsin S, K, F, L and B reversible inhibitory amidino and guanidino peptidyl compounds useful for treating autoimmune diseases, rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis |
| 02/03/2005 | US20050026875 Treating bacterial, viral, or fungal infections, cancer, a lung injury, an eye disorder, neurological disorder or stroke |
| 02/03/2005 | US20050026863 Delivery of therapeutic gene products by intestinal cell expression |
| 02/03/2005 | US20050026846 Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism |
| 02/03/2005 | US20050026840 Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or pertidomimetics |
| 02/03/2005 | US20050026251 Netrin receptor protein for use in identification of modulator for use in treatment and prevention of infection, nervous system, autoimmune, inflammatory, psycological and reproductive disorders |
| 02/03/2005 | US20050026233 Using bioassay for loss-of-function mutations in protein kinase (LKB1) as diagnostic tool in detection of cell proliferative disorders; AMP-activated protein kinase (AMPK) and treatment of diabetic, cardiovascular and dietetic disorders |
| 02/03/2005 | US20050025806 A silicone support of methylvinylsiloxane polymer including a fumed silca reinforcement filler; growth and/or reproduction-associated drug, derivative or analogue and carrier; each implant of insufficient size and/or payload for the predetermined threshold blood level of indicated drug; high-speed |
| 02/03/2005 | US20050025751 Increased or reduced expression of tumor necrosis factors or interleukins; antiinflammatory agents; autoimmune diseases |
| 02/03/2005 | DE10335092B3 Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung Benzoylureido substituted-o-benzoylamide, processes for their preparation and their use |
| 02/03/2005 | CA2770493A1 Cyclohexanecarboxylic acid compound |
| 02/03/2005 | CA2533402A1 A1 adenosine receptor antagonists |
| 02/03/2005 | CA2528586A1 Cyclohexanecarboxylic acid compound |
| 02/03/2005 | CA2524184A1 Microbial cellulose wound dressing comprising phmb |
| 02/02/2005 | EP1502598A2 Lipolysis stimulator |
| 02/02/2005 | EP1502596A1 Herbal product to be administered to diabetic individuals and the production method thereof |
| 02/02/2005 | EP1502590A1 Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes |
| 02/02/2005 | EP1502588A1 Light-stabilized soft capsule for formulations |
| 02/02/2005 | EP1501936A2 Cytokine protein family |
| 02/02/2005 | EP1501930A2 Oligomeric compounds for the modulation hif-1alpha expression |
| 02/02/2005 | EP1501919A1 Soya cell strains with high isoflavone content |
| 02/02/2005 | EP1501862A2 Novel analogues of glucose-dependent insulinotropic polypeptide |
| 02/02/2005 | EP1501834A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501833A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501830A1 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases |
| 02/02/2005 | EP1501819A1 Estrogen receptor modulators |
| 02/02/2005 | EP1501817A1 Imidazolinylmethyl aralkylsulfonamides |
| 02/02/2005 | EP1501815A1 Substituted phenylacetamides and their use as glucokinase activators |
| 02/02/2005 | EP1501813A2 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| 02/02/2005 | EP1501808A1 Tachykinin receptor antagonists |
| 02/02/2005 | EP1501803A2 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
| 02/02/2005 | EP1501800A1 Bombesin antagonists |
| 02/02/2005 | EP1501791A1 Amino acid analogues |
| 02/02/2005 | EP1501566A1 Medical products comprising a haemocompatible coating, production and use thereof |
| 02/02/2005 | EP1501565A1 Compounds and method for coating surfaces in a haemocompatible manner |
| 02/02/2005 | EP1501545A2 Use of tnfalpha antibodies and another drug |
| 02/02/2005 | EP1501525A1 Method for producing preparations rich in tocotrienol |
| 02/02/2005 | EP1501520A1 Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels |
| 02/02/2005 | EP1501515A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501512A2 4-azasteroid derivatives as androgen receptor modulators |
| 02/02/2005 | EP1501511A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway |
| 02/02/2005 | EP1501504A1 1-substituted imidazole derivatives as nos inhibitors |
| 02/02/2005 | EP1501498A1 Pharmaceutical composition comprising a lipase inhibitor and glucomannan |
| 02/02/2005 | EP1501487A1 Capsule preparation |
| 02/02/2005 | EP1501482A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| 02/02/2005 | EP1501467A2 Heterocyclo inhibitors of potassium channel function |
| 02/02/2005 | EP1436382A4 9136, a human aldehyde dehydrogenase family member and uses therefor |
| 02/02/2005 | EP1303521B1 Tetrahydro-heterocycloazepinyl pyrimidine derivatives |
| 02/02/2005 | EP1285269B1 Lipid uptake assays |
| 02/02/2005 | EP1280812B1 Cyclipostins, a method for their production and the use of the same |
| 02/02/2005 | EP1175390B1 Disodium salts, monohydrates, and ethanol solvates |
| 02/02/2005 | EP1165534B1 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments |
| 02/02/2005 | EP1161235B1 Combinations for the treatment of diseases involving angiogenesis |
| 02/02/2005 | EP1124779B1 Vitamin d analogues |
| 02/02/2005 | EP0828754B1 Dipeptides which promote release of growth hormone |
| 02/02/2005 | EP0757557B1 Methods for inducing t cell tolerance to a tissue or organ graft |
| 02/02/2005 | CN1575337A Mammalian receptor proteins; related reagents and methods |
| 02/02/2005 | CN1575290A Pyrimidine derivatives and pharmaceutical compositions containing that compounds |
| 02/02/2005 | CN1575289A 6-hydroxy isoflavon compounds, their derivatives and medicaments involving the same |
| 02/02/2005 | CN1575287A Alpha-form or beta-form crystal of acetanilide derivative |
| 02/02/2005 | CN1575191A Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors |
| 02/02/2005 | CN1575182A Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/02/2005 | CN1575180A Antidiabetic 2-substituted-5'-o- (1-boranotriphosphate) adenosine derivatives |
| 02/02/2005 | CN1575177A Cxcr3 antagonists |
| 02/02/2005 | CN1575176A Process for making substituted pyrazoles |
| 02/02/2005 | CN1575173A Macrolides containing pharmaceutical compositions |
| 02/02/2005 | CN1575172A Substituted ideno[1, 2-c]isoquinoline derivatives and methods of use thereof |
| 02/02/2005 | CN1575171A Novel anti-diabetic agents |
| 02/02/2005 | CN1575170A (-)-1-(3, 4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 02/02/2005 | CN1575169A Mch antagonists for the treatment of obesity |